Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 781,981
  • Shares Outstanding, K 13,671
  • Annual Sales, $ 213,310 K
  • Annual Income, $ 31,900 K
  • 60-Month Beta 1.43
  • Price/Sales 3.64
  • Price/Cash Flow 23.57
  • Price/Book 4.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.07
  • Number of Estimates 1
  • High Estimate 0.07
  • Low Estimate 0.07
  • Prior Year 0.86
  • Growth Rate Est. (year over year) -91.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.90 +3.52%
on 11/14/19
64.94 -12.49%
on 11/04/19
-4.88 (-7.91%)
since 10/18/19
3-Month
53.69 +5.86%
on 09/03/19
64.94 -12.49%
on 11/04/19
-1.23 (-2.12%)
since 08/16/19
52-Week
36.03 +57.73%
on 12/24/18
64.94 -12.49%
on 11/04/19
+6.17 (+12.18%)
since 11/16/18

Most Recent Stories

More News
Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Douglas L. Braunstein is stepping down from the Company's Board of Directors, effective November 14, 2019. Mr....

EGRX : 56.83 (-0.65%)
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -16.13% and -5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

EGRX : 56.83 (-0.65%)
Eagle Pharmaceuticals: 3Q Earnings Snapshot

WOODCLIFF LAKE, N.J. (AP) _ Eagle Pharmaceuticals Inc. (EGRX) on Tuesday reported a third-quarter loss of $2.4 million, after reporting a profit in the same period a year earlier.

EGRX : 56.83 (-0.65%)
Eagle Pharmaceuticals Reports Third Quarter 2019 Results

-- Plan to initiate a clinical trial in December for Eagle's innovative fulvestrant program, which has the potential to result in greater inhibition of estrogen receptors and better outcomes for patients...

EGRX : 56.83 (-0.65%)
Eagle Pharmaceuticals Announces Enrollment of Additional Exertional Heat Stroke Patients at the 2019 Hajj Pilgrimage

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today provided an update on the Company's program for RYANODEX(R) (dantrolene sodium for injectable suspension) for the treatment of...

EGRX : 56.83 (-0.65%)
Eagle Pharmaceuticals to Discuss Third Quarter 2019 Financial Results on November 12, 2019

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2019 third quarter financial results on Tuesday, November 12, 2019, before the market...

EGRX : 56.83 (-0.65%)
Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EGRX : 56.83 (-0.65%)
Eagle Pharmaceut Has Returned 11.4% Since SmarTrend Recommendation (EGRX)

SmarTrend identified an Uptrend for Eagle Pharmaceut (NASDAQ:EGRX) on July 1st, 2019 at $56.11. In approximately 4 months, Eagle Pharmaceut has returned 11.43% as of today's recent price of $62.52.

EGRX : 56.83 (-0.65%)
New Strong Sell Stocks for October 17th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

ARCB : 28.66 (-1.82%)
CVCY : 20.94 (+0.19%)
BGS : 16.28 (-0.43%)
EGRX : 56.83 (-0.65%)
TS : 21.51 (-1.74%)
Eagle Pharmaceuticals' Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM(R) Ready-To-Dilute Formulation

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited ("SymBio") has submitted a New Drug Application ("NDA") for...

SYMQY : 2.4500 (unch)
EGRX : 56.83 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade EGRX with:

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

2nd Resistance Point 58.32
1st Resistance Point 57.57
Last Price 56.83
1st Support Level 56.08
2nd Support Level 55.34

See More

52-Week High 64.94
Last Price 56.83
Fibonacci 61.8% 53.90
Fibonacci 50% 50.49
Fibonacci 38.2% 47.07
52-Week Low 36.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar